OBJECTIVES: Treatments for stroke and other brain injuries are limited. NuroAiD II (MLC 901) is a combination of natural products has been used to improve recovery after ischemic stroke.
AIM: The aim of this study was to assess the safety and potential efficacy of NuroAiD II in the early stage post stroke, not later than six months after stroke onset in the Eastern European population.
MATERIAL AND METHODS: The NeuroAiD Safe Treatment (NeST) Registry (clinicaltrials.gov NCT02536079) is a product registry provides information on the use and safety of NeuroAiD in clinical practice. We analysed anonymized information of ischemic injury from Slovakia and Poland. Patients consented are prospectively entered using online forms for baseline and subsequent visits. Data collected includes demographics, diagnosis, medical history, modified Rankin Score (mRS), Glasgow Coma Scale (GCS), National Institute of Health Stroke Scale (NIHSS), compliance, and side effects.       
RESULTS: Twenty-nine consecutive patients from Slovakia and Poland were included with mean age of 62.29±12.51 years, with 12 (41.38%) women. Median NIHSS for the patients was 7 (1-23) at baseline, 6 (0-17) at M (month) 1, 4 (0-16) at M2 and 3 (0-15) at M3 (Figure 1). mRS was improving over time (Figure 2). There were no side effects reported. One patient was lost of follow-up. 
CONCLUSIONS: NuroAiD II was safe in ischemic stroke in two Eastern European countries who improved on functional and neurological measures.
Reference:
Narayanaswamy Venketasubramanian et al. The NeuroAiD Safe Treatment (NeST) Registry: a protocol. BMJ Open 2015;5:e009866. doi:10.1136/bmjopen-2015-
009866.

NEUROAID EARLY POST STROKE: PRELIMINARY RESULTS OF A MULTICENTRE STUDY